Survival analysis indicated that the BCR-free time of the high risk PCa patients was markedly shorter than that of its counterpart (Figure 3A), which was validated in internal and external cohorts, namely the testing TCGA-PRAD cohort, the entire TCGA-PRAD cohort, and GSE21034 cohort (Figures 3B-D). The gene discussed is BCR; the disease is posterior cortical atrophy.